These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 22021624)

  • 1. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.
    Srivastava S; Pasipanodya JG; Meek C; Leff R; Gumbo T
    J Infect Dis; 2011 Dec; 204(12):1951-9. PubMed ID: 22021624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.
    Gumbo T
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1484-91. PubMed ID: 20086150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling.
    Srivastava S; Sherman C; Meek C; Leff R; Gumbo T
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5085-9. PubMed ID: 21896907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.
    Pasipanodya JG; Srivastava S; Gumbo T
    Clin Infect Dis; 2012 Jul; 55(2):169-77. PubMed ID: 22467670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Trends in tuberculosis treatment duration].
    Veziris N; Aubry A; Truffot-Pernot C
    Presse Med; 2006 Nov; 35(11 Pt 2):1758-1764. PubMed ID: 17086138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment duration for patients with drug-resistant tuberculosis, United States.
    Winston CA; Mitruka K
    Emerg Infect Dis; 2012 Jul; 18(7):1201-2. PubMed ID: 22709909
    [No Abstract]   [Full Text] [Related]  

  • 7. Concomitant increases in spectrum and level of drug resistance in Mycobacterium tuberculosis isolates.
    Sun Z; Zhang J; Song H; Zhang X; Li Y; Tian M; Liu Y; Zhao Y; Li C
    Int J Tuberc Lung Dis; 2010 Nov; 14(11):1436-41, i. PubMed ID: 20937184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.
    Zuur MA; Pasipanodya JG; van Soolingen D; van der Werf TS; Gumbo T; Alffenaar JC
    Clin Infect Dis; 2018 Nov; 67(11):1743-1749. PubMed ID: 29697766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Attributable factors to the emergence of multidrug-resistant Mycobacterium tuberculosis based on the observation of consecutive drug resistance test results].
    Fujino T; Hasegawa N; Satou R; Komatsu H; Kawada K
    Kekkaku; 1998 Jul; 73(7):471-6. PubMed ID: 9739579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
    Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.
    Chakraborty S; Rhee KY
    Cold Spring Harb Perspect Med; 2015 Apr; 5(8):a021147. PubMed ID: 25877396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secretome profile analysis of multidrug-resistant, monodrug-resistant and drug-susceptible Mycobacterium tuberculosis.
    Putim C; Phaonakrop N; Jaresitthikunchai J; Gamngoen R; Tragoolpua K; Intorasoot S; Anukool U; Tharincharoen CS; Phunpae P; Tayapiwatana C; Kasinrerk W; Roytrakul S; Butr-Indr B
    Arch Microbiol; 2018 Mar; 200(2):299-309. PubMed ID: 29119205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis.
    Somoskovi A; Parsons LM; Salfinger M
    Respir Res; 2001; 2(3):164-8. PubMed ID: 11686881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consequences of noncompliance for therapy efficacy and emergence of resistance in murine tuberculosis caused by the Beijing genotype of Mycobacterium tuberculosis.
    de Steenwinkel JE; ten Kate MT; de Knegt GJ; Verbrugh HA; Aarnoutse RE; Boeree MJ; den Bakker MA; van Soolingen D; Bakker-Woudenberg IA
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4937-44. PubMed ID: 22802244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Polyphenolic Profile and Antibacterial Activity of Pomegranate Juice in Combination with Rifampin (R) against MDR-TB Clinical Isolates.
    AlMatar M; Var I; Kayar B; Eker E; Kafkas E; Zarifikhosroshahi M; Köksal F
    Curr Pharm Biotechnol; 2019; 20(4):317-326. PubMed ID: 30854955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis.
    Mvelase NR; Balakrishna Y; Lutchminarain K; Mlisana K
    BMJ Open; 2019 Nov; 9(11):e031663. PubMed ID: 31699736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bactericidal action of pulsed exposure to rifampicin, ethambutol, isoniazid & pyrazinamide on Mycobacterium tuberculosis in vitro.
    Paramasivan CN; Herbert D; Prabhakar R
    Indian J Med Res; 1993 Jul; 97():145-50. PubMed ID: 8406638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland].
    Napiórkowska A; Augustynowicz-Kopeć E; Zwolska Z
    Pneumonol Alergol Pol; 2010; 78(4):256-62. PubMed ID: 20665445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology of drug-resistant tuberculosis in New Jersey from 1991 to 1995.
    Liu Z; Shilkret KL; Finelli L
    Int J Epidemiol; 1998 Feb; 27(1):121-6. PubMed ID: 9563705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.